A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients with Glioblastoma Multiforme

Study identifier:1839IL/0088

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa™) and Radiotherapy in the Treatment of Patients with Glioblastoma Multiforme

Medical condition

Glioblastoma

Phase

Phase 2

Healthy volunteers

No

Study drug

Gefitinib

Sex

All

Actual Enrollment

36

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2003
Primary Completion Date: -
Study Completion Date: 01 Mar 2006

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria